Serum Chemerin and thyrotropin expression levels in patients with thyroid cancer and roles in predicting survival

Objective: In the current study, the relationship between expression levels of Chemerin (Chemerin), thyrotropin (TSH), and prognosis in serum of patients with thyroid cancer was explored. Methods: Serum TSH levels in 110 patients with thyroid cancer (observation group) and 100 patients with benign thyroid lesions (control group) were measured using enzyme-linked immunosorbent assays (ELISA). Expression patterns of Chemerin and TSH of the observation group were analyzed. Survival analysis was performed on patients in the observation group. Kaplan-Meier estimates were performed with recurrent and non-recurrent patients as dependent variables. ROC curves were used to analyze the diagnostic value of Chemerin and TSH for thyroid cancer. Results: Chemerin and TSH expression levels in serum of the observation group were significantly higher than those of the control group (P<0.05). There was a correlation between TNM stage and lymph node metastasis (P<0.05). The area under the ROC curve of Chemerin, TSH, and their combination for diagnosis of thyroid cancer was 0.854 (95% CI: 0.803 similar to 0.905), 0.701 (95% CI: 0.630 similar to 0.773), and 0.880 (95% CI: 0.834 similar to 0.926), respectively. The 5-year overall survival of 110 patients with thyroid cancer was 54.55%. Further analysis found that 5-year survival rates of the Chemerin high expression group were significantly lower than those of the Chemerin low expression group (P=0.001). TSH high expression and TSH low expression groups showed a similar trend (P=0.007). Conclusion: Chemerin and TSH have diagnostic value in thyroid cancer. They are expected to be potential predictors of survival.